Evidence map›Paper›PMID 33389656›Full record

ArticleInternational journal of hematology2021

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.

Juan Du, Baijun Fang, Jian Li, Jie Jin, Shunqing Wang, Dehui Zou, Zhen Cai, Hongxiang Wang, Jianda Hu, Wei Li and 9 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03029234 (An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03029234 phase3completednot on this map

An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China

TypeinterventionalSponsorAmgenRan2017 to 2021Enrolled126ConditionsRelapsed and Refractory Multiple MyelomaArmsDexamethasone, Carfilzomib
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 2 countries.

Juan DuDepartment of Hematology, Shanghai Changzheng Hospital, Shanghai, China.
Baijun FangDepartment of Hematology, Henan Cancer Hospital, Zhengzhou, Henan, China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
Shunqing WangDepartment of Hematology, Guangzhou First People's Hospital, Guangzhou, Guangdong, China.
Dehui ZouDepartment of Lymphoma and Myeloma, Institute of Hematology and Hospital of Blood Disease, Tianjin, China.
Zhen CaiDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
Hongxiang WangDepartment of Hematology, Central Hospital of Wuhan, Wuhan, Hubei, China.
Jianda HuDepartment of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Wei LiDepartment of Hematology, The First Hospital of Jilin University, Changchun , Jilin, China.
Chengcheng FuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zonghong ShaoDepartment of Hematology and Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Zhongjun XiaDepartment of Hematology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Ting NiuDepartment of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
En-Tzu TangGlobal Biometric Data Science, Amgen Inc., Shanghai, China.
Amy S KimballGlobal Development, Amgen Inc, Thousand Oaks, CA, USA.
Jian HouDepartment of Hematology, Shanghai Renji Hospital, 160 Pujian Road, Pudong New District, Shanghai, China. houjian@medmail.com.cn.
Wenming ChenDepartment of Hematology, Beijing Chao Yang Hospital, Capital Medical University, 8 Gongti South Road, Beijing, 100020, China. 13910107759@163.com.
First Affiliated Hospital Zhejiang University · CNAmgen (United States) · USBeijing Chao-Yang Hospital · CNCentral Hospital of Wuhan · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Soochow University · CNFudan University · CNGuangzhou Medical University · CNHenan Cancer Hospital · CNInstitute of Hematology & Blood Diseases Hospital · CNJilin University · CNRenji Hospital · CNShanghai Changzheng Hospital · CNSichuan University · CNSun Yat-sen University · CNTianjin Medical University General Hospital · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The second-generation proteasome inhibitor carfilzomib produces superior outcomes in relapsed or refractory multiple myeloma (MM). We conducted a single-arm trial of twice-weekly carfilzomib (27 mg/m

Indexed as

Salvage TherapyAcute Kidney InjuryAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChinaCombined Modality TherapyDexamethasoneDrug Resistance, NeoplasmFemaleHeart DiseasesHematopoietic Stem Cell TransplantationHumansHypertensionKaplan-Meier EstimatecarfilzomibDexamethasoneOligopeptidesCarfilzomibChinaProteasome inhibitorRelapsed and refractory multiple myelomaSingle-arm

Identifiers

PMID33389656
OpenAlexW3191911429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.